Cost-effectiveness of a potential future heficobacter pylori vaccine in the netherlands; the impact of varying the discount rate for health

摘要

Introduction: The two most important clinical conditions, which are associated with Helicobacter pylori infection, both in numbers and costs are peptic ulcer disease and gastric cancer. In 1999 these two conditions were responsible for more than 2000 deaths and 94,9 million in the Netherlands In this paper we calculate the cost-effectiveness of a potential Helicobacter pylori vaccine. Additionally, the impact of changing the discount rate for health, as is now suggested for the Netherlands, is shown.